Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 17.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 2,305 shares, a drop of 17.5% from the February 26th total of 2,795 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 11,098 shares, the short-interest ratio is currently 0.2 days.

Global X Genomics & Biotechnology ETF Stock Up 5.7%

Shares of GNOM traded up $2.34 during mid-day trading on Tuesday, reaching $43.74. The company had a trading volume of 2,789 shares, compared to its average volume of 9,829. Global X Genomics & Biotechnology ETF has a 52-week low of $27.20 and a 52-week high of $51.42. The stock has a market capitalization of $47.68 million, a P/E ratio of -18.69 and a beta of 1.22. The stock has a 50 day moving average of $46.01 and a two-hundred day moving average of $44.61.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC raised its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares during the period. Flow Traders U.S. LLC grew its holdings in Global X Genomics & Biotechnology ETF by 52.4% in the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after purchasing an additional 82,063 shares during the period. Sei Investments Co. increased its position in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after buying an additional 4,615 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after buying an additional 489 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.